Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018756 | 1.00 | JAK3 (0.43) | JAK3ROCK2ROCK1CDC42BPBNMT1 | |
| SCHEMBL3961208 | 0.81 | JAK3 (0.66) | JAK3JAK2JAK1SCN9AMETAP2 | |
| SCHEMBL29869816 | 0.74 | ROCK2 (0.65) | JAK3ROCK2ROCK1CDC42BPBJAK2 | |
| SCHEMBL7852410 | 0.74 | JAK3 (0.55) | JAK3JAK2JAK1SCN9AMETAP2 | |
| SCHEMBL2016028 | 0.73 | PAK4 (0.47) | FFAR2 | |
| SCHEMBL2016025 | 0.73 | PAK4 (0.47) | FFAR2 | |
| SCHEMBL25528819 | 0.72 | CRHR1 (0.39) | NMT1ADORA2ACRHR1CNR2SCN9A | |
| SCHEMBL2017273 | 0.72 | BRD4 (0.54) | JAK3JAK2SCN9A | |
| SCHEMBL2017271 | 0.72 | BRD4 (0.54) | JAK3JAK2SCN9A | |
| SCHEMBL25528220 | 0.70 | ACVR1 (0.46) | NMT1ADORA2ACRHR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885ROCK2 1102/4885ROCK1 834/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885ROCK2 1102/4885ROCK1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.